Enterosorbent

 

(57) Abstract:

The invention can be used in medicine. Enterosorbent contains activated carbon, microcrystalline cellulose, and optionally, the pectin in the following ratio, wt.%: the activated carbon 50-90, MCC 5-30, pectin 5-20. The invention allows to improve therapeutic and prophylactic properties of the product, to expand the range.

The invention relates to medicine and can be used as enterosorbent.

A method of obtaining tablets of enterosorbent by mixing activated carbon with microcrystalline cellulose (MCC) - RF Patent 2129425, IPC And 61 To 33/44, 47/38, 9/20.

Disadvantages: prolonged use of the sorbent can lead to constipation and excretion of a physiological ion.

The objective of the invention is the improvement of therapeutic and preventive properties of enterosorbent, prevention of side effects, the expansion of the range.

These objectives are achieved with the help of enterosorbent "Carbopack" consisting of activated charcoal, microcrystalline cellulose (MCC) and the addition of pectin, in the following ratio, wt.%:

Coal activity and radionuclides.

MCC promotes the excretion of toxic substances, radionuclides, products of metabolism, contributes to the normalization of the intestinal microflora, activates the large intestine.

Pectin helps to eliminate heavy metals and toxins, reduces cholesterol level in blood.

Method of preparation: 50-90 g of activated charcoal mixed with 5-30 g MCC, add 5-20 g of pectin, mix until smooth, moisturize purified water to obtain a pasty mass. The mixture granularit, dried and tabletirujut. Get pills weight 0,5 g

Examples of specific performance.

Example 1. 50 g of activated charcoal mixed with 30 g of MCC and 20 g of pectin, moisturize purified water. The mixture granularit, dried and tabletirujut. Get pills weight 0,5 g

Example 2. 90 g of activated charcoal mixed with 5 g of MCC and 5 g of pectin, moisturize purified water. The mixture granularit, dried and tabletirujut 0.5 g

"Carbopack" - a successful combination of activated carbon, MCC and pectin, which significantly increases the efficiency of each component and eliminates the adverse effects of activated charcoal (eg, constipation).

Enterosorbent, strophulus, atopic dermatitis, urticaria and angioedema, psoriasis, allergic sinusitis, bronchial asthma, recurrent stenosis of the upper respiratory tract, recurrent obstructive bronchitis, intestinal dysbiosis, reactive hepatitis, reactive pancreatitis, acute intestinal infection, food intoxication, household poisoning, prevention of population with ecologically disadvantaged areas, children at-risk groups for the development of allergic diathesis.

Enterosorbent "Carbopack" use 5 tablets 3 times daily with water. Children are encouraged 1/2 adult dose.

Side effects are absent.

Contraindications none known.

Clinical examples.

Example 1.

Borisov Misha, 8 months

Diagnosis: atopic dermatitis, a limited form; intestinal dysbiosis.

The clinic before treatment: the skin is dry, erythema of the cheeks. Liver +1,5. Liquid stools 3-4 times a day.

Data from laboratory studies:

OAK before treatment - er 4,4, HB 123, Le 11, eosin. 6%.

A smear from a nose on eosinophilia: E. 6%, N. 0%.

The immunological before treatment: leukocytosis 11%, lymphocytosis 76%, decreased T-l - 46%, increase T-TFF. - 47%, reduced T-TFC. - 11%. With the change of the liver. Reactive pancreatitis.

The analysis of a feces on a dysbacteriosis: improved the content of the E-coli - 4,6108, enterococci - 1,6108and Gamal. E-coli - 1,2108. Bifidum-bacteria 108- normal.

Received "Carbopack" in a dose of 1 tab. 3 times a day. The course is 21 days.

Clinic after treatment: the skin is clean, dry is not observed, elastic. The abdomen is soft. Liver a +0.5. Normalization of stools, 2 times a day, pasty.

OAK after treatment - er 4,5, HB 150, Le 6,0, eosin 2%.

A smear from a nose on eosinophilia: E. 1%, N. 1%.

The immunological after treatment: Le 8.0 (normal). Saved lymphocytosis - 74%; normalization of T-limp. 54.6% of T-TFF. - 46%, T-TFC. - 17%. The level of Ig And 0.8, The Ig of 7.4 G, Ig M 0,41 - normal. Phagocytosis is normal.

The analysis of a feces on a dysbacteriosis: Bifidum - 10 bacteria and E-coli 107- OK, lactose-negative E-coli 106.

Ultrasound of the gastrointestinal tract: the liver is not enlarged, remain reactive changes in the pancreas.

Example 2.

Chernousov Maxim, 10 months.

Diagnosis: atopic dermatitis, plaque form.

The clinic before treatment: the skin is dry, on the right leg two plaques size 2,02,0. Liver +and 1.0. The abdomen is soft. Chair regular.

DIU: E. 70%, ad 30%.

The immunological before treatment: leukocytosis with 11.2% decrease in T-l - 38%, T-active - 25%, T-TFF. - 15%, T-TFC. - 12%. Ig A - traces, reduced Ig G to 6.0, Ig M - 0.93 (in norm). Phagocytosis in normal.

Ultrasound of the gastrointestinal tract before treatment: liver +1,0, Reactive changes in the liver.

Received "Carbopack" in a dose of 1 tab. 3 times a day. The course is 21 days.

Clinic after treatment: the skin clean, supple. The abdomen is soft. Liver a +0.5. Chair regular.

OAK after treatment - er 4,5, HB 126, Le 7,0, eosin. 2%.

A smear from a nose on eosinophilia: 30 E.% of N. 70%.

The immunological after treatment: Le 8.0 (normal), normalization of T-limp. - 54,0%, T-active - 30%, T-TFF. - 36%, T-TFC. -18%. Normalization humoral (level Ig 0.7, Ig G 6,3, Ig M to 0.8). Phagocytosis in normal.

Ultrasound of the gastrointestinal tract: the liver is not enlarged, the morphological changes are not detected.

Example 3.

Vitaly Maksimov, 1 year and 8 months.

Diagnosis: atopic dermatitis, a common form.

The clinic before treatment: the face is dry, the skin on the chest, abdomen, upper extremities covered with a maculopapular rash on the face rash drain. Cyanosis of nasolabial triangle. Belly swollen. Liver +2,0. The tendency to constipation.

These laboratories is%.

The immunological before treatment: leukocytosis 11,8, General T-lymphopenia -33%, decreased cellular immunity (T-active 13%, T-TFF. 20%, reduction of T-TVC. (-)). The decline of humoral (Ig A 0,29, Ig of 3.7 G, Ig M 0,8).

Ultrasound of the gastrointestinal tract before treatment: liver +2,0. Reactive changes in the liver, pancreas.

Received "Carbopack" in a dose of 1 tab. 3 times a day. The course is 21 days.

Clinic after treatment: the skin clean, somewhat dry, rash no. The abdomen is soft. Liver +and 1.0. Chair 2 times a day.

OAK after treatment - er 5,0, HB 150, Le 9,0, eosin. 2%.

A smear from a nose on eosinophilia: E. 0%, N. 11%.

The immunological after treatment: normalization of parameters of the T-link (agg T-limp. 84% active E-ROCK 35%, T-TFF. 42%, T-TFC. 10%). The level of Ig And 2,07, Ig of 5.05 G, Ig M 0,87 - normal.

Ultrasound of the gastrointestinal tract: liver +and 1.0. Saved reactive changes in the pancreas.

Example 4.

Kabanova Olesya, 2 years and 8 months.

Diagnosis: atopic dermatitis, a limited form.

The clinic before treatment: the skin is dry, drain maculata rash on face and chest. The abdomen is soft. Liver +1,5. Chair decorated.

Data from laboratory studies: OAK before treatment - er 4,2, HB 122, Le 8,3, eosin. 5%.

the moral of the link - Ig And 0.45, Ig 3,0 G, Ig M 0,70.

Ultrasound of the gastrointestinal tract before treatment: Reactive changes in the liver.

Received "Carbopack" in a dose of 1 tab. 3 times a day. The course is 21 days.

Clinic after treatment: the skin clean, supple. The abdomen is soft. Liver a +0.5. Chair decorated.

OAK after treatment - er 4,5, HB 144, Le 7,2, eosin. 1%.

A smear from a nose on eosinophilia: E. 2% N. 5%.

The immunological after treatment: normalizing the total number of T-lymphocytes 60%, the tendency to normalization of T-TFF. - 53%, T-TFC. - 21% and humoral Ig 0.9, Ig of 5.7 G, Ig M 1,23.

Ultrasound of the gastrointestinal tract: normalization of liver size, morphological changes are not detected.

Example 5.

Spirina Arina, 4 months.

The diagnosis of seborrheic eczema, intestinal dysbiosis.

The clinic before treatment: the skin is dry behind the ears hyperemia, infiltration, desquamation. Point xerosis across the surface of the skin, erythema of the cheeks with the crusts. Liver and +2.5. Liquid stools 3-4 times a day.

Data from laboratory studies: OAK before treatment - er 4,0, HB 123, Le 7,4, eosin. 8%.

A smear from a nose on eosinophilia: E. 12%, N. 1%.

The immunological before treatment: Leukocytosis 13,4%, T-limp. 54% (upper limit of normal), increased T-active - 41%, T-TFF. 69%, T-TFC.- (-). recommended reading: liver +3,0. Marked reactive changes in the liver. Reactive pancreatitis.

The analysis of a feces on a dysbacteriosis: E-coli 8,0108the absence of lactic acid, lactose-negative, bifidum bacteria.

Received "Carbopack" in a dose of 1 tab. 3 times a day. The course is 21 days.

Clinic after treatment: the skin is clean, a little dryness. The abdomen is soft. Liver +and 1.0. Normalization of stools, 2 times a day, pasty.

OAK after treatment - er 4,1, HB 128, Le 9,0, eosin. 3%.

A smear from a nose on eosinophilia: E. 1% N. 5%.

The immunological after treatment: Le-8,5 (within limits), the tendency to normalization of active E-ROCK - 38%, T-TFF. - 49%, T-TFC. - 10%. The level of Ig And 0,81, Ig of 4.6 G, Ig M 0,89 - normal. Phagocytosis indices are normal.

The analysis of a feces on a dysbacteriosis: the emergence of bifido-bacteria 104E-coli 108and enterococci 106(in norm), the absence of lactic acid, lactose-negative bacteria.

Ultrasound of the gastrointestinal tract: liver +1,0; saved reactive changes in the pancreas.

Enterosorbent consisting of activated charcoal and microcrystalline cellulose (MCC), characterized in that it additionally contains pectin in the following ratio, wt. %:

Coal activities is

 

Same patents:

The invention relates to medicine, namely to dermatology, and can be used in the treatment of eczema and psoriasis

The invention relates to medicine and concerns the establishment of a drug for the treatment of purulent skin infections

The invention relates to medicine and can be used for the treatment of venous leg ulcers

The invention relates to new Bermatingen compounds, the United propylenebis communication, General formula I where Ar represents a radical of formula (a) or (b), R1is-OR6or-COR7, R2represents a polyether radical, comprising 1 to 6 carbon atoms and 1 to 3 atoms of oxygen or sulfur, and if in the latter case, R4represents a linear or branched C1-C20alkyl, he is in ortho - or meta-position relative to X-Ar connection, R3represents lower alkyl, or R2or R3taken together form a 6-membered ring, optionally substituted by at least one of the stands and/or optional split the atom of oxygen or sulfur, R4represents H, linear or branched C1-C20alkyl or aryl, R5represents H or-OR8, R6represents H, R7represents H, -OR10or-N(r)r (r) r are H, lower alkyl or taken together with the nitrogen atom form a ring of morpholino, R8represents H or lower alkyl, R10represents H, linear or branched C1-C20alkyl, X represents a divalent radical, which is from right to left or Vice versa has the formula (d), R11Fri carboxylic acid and the optical and geometrical isomers of the above compounds of formula (I)

The invention relates to medicine

The invention relates to medicine, namely to the treatment of ulcers in the diabetic foot syndrome

The invention relates to medicine, to compositions for skin care containing 0.001 to 10.0% of retinol or its ether complex, 0,0001-50.0% inhibitor reaction of esterification of retinol (N-substituted fatty acid amide) and the media
The invention relates to medicine, to surgery, to a method of treatment of fistulous dermatitis
The invention relates to medicine, in particular to plastic surgery, and can be used for the treatment of burn wounds
Enterosorbent // 2180230
The invention relates to medicine

The invention relates to medicine, in particular for the treatment of patients with liver diseases, and the development of a treatment method that increases the effectiveness of therapy by improving the hemodynamics of the liver
The invention relates to medicine, to therapy, to method chronotherapy glucocorticoids patients with bronchial asthma, severe

The invention relates to medicine, namely to dermatology, and can be used in the treatment of eczema and psoriasis
The invention relates to medicine, namely to sexologist
The invention relates to medicine, in particular to the drug for inhalation, representing a dry powder composition comprising formoterol and substance-media, which are in fine form, and the drug has a loose bulk density of 0.28 - 0,38 g/ml and is useful in the treatment of respiratory disorders, and also relates to a method for obtaining a composition and to a method of treatment of a patient suffering from a respiratory disorder

The invention relates to medicine and concerns the establishment of a drug for the treatment of purulent skin infections
The invention relates to medicine, more specifically to oncourology, and may find application in the treatment of malignant tumors of the kidney with metastases

The invention relates to medicine, in particular to a gastroenterologist, and for the treatment of gastroduodenal ulcers
The invention relates to medicine
The invention relates to medicine, in particular to therapy, and for the treatment of diseases accompanied by increased levels of endotoxin in the blood, including in gerontology
Up!